Weekly Rounds: Hot Topics in IPC, Infection Intel, Inhaled Therapies for Lung Functions, and More
Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending November 5, 2023.
Here are 5 highlights from Infection Control Today®'s (ICT®’s) wide-ranging coverage of the infection prevention and control world. Everything from interviews with known opinion leaders to the news that infection preventionists and other health care professionals can use on their jobs.
Hot Topics in IPC: Influenza, COVID-19, and Mechanical Ventilation and Drug-Resistant Pathogens
In this Hot Topics in IPC, Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC, discusses her concerns about COVID-19 and influenza for this winter, and mechanical ventilation and drug-resistant pathogens.
Infection Intel: Chicopee, GP Pro, US FDA, and Henry Schein
Staying Ahead With Company Updates and Product Innovations. This week's news is from Chicopee, GP Pro, US FDA, and Henry Schein.
Qnovia Collaborates With UVA to Develop Novel Inhaled Therapies for Lung Infections
Pharmaceutical company Qnovia partners with the University of Virginia (UVA) to create inhaled drugs for lung infections, bolstering their development pipeline with assets for pneumonia and biodefense-related pulmonary infections.
CDC Advises on Limited Nirsevimab Supply and RSV Protection Options
The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.
Encouraging Results Emerge from Phase 1/2 Study of mRNA-Based Influenza and COVID-19 Combo Vaccines
With a safety profile consistent with Pfizer’s COVID-19 vaccine, this combination vaccine candidate will most likely be moving to a phase 3 trial in the coming months.
